Content and data provided by various third parties and Fidelity − Terms of Use | Help/Glossary
Research > ETFs > ETF / ETP Commentary > 

Powerhouse AI ETF DRAM Hits $6.5 Billion at Record Pace

BY | ETF Database
05/11/2026 | 76 VIEWS
Generally speaking, investors and advisors take notice when an ETF with an interesting approach hits a key AUM milestone. As is the case with the Roundhill Memory ETF (DRAM). The fund keeps hitting milestone after milestone after milestone — all within less than two months of it being online. Key Takeaways: Despite being on the market for less than 40 days, the Roundhill Memory ETF (DRAM) has already reached $6.5 billion in AUM. Per Eric Balchunas of Bloomberg, DRAM reached $6.5 billion at the fastest rate of any ETF on the market, beating out IBIT’s previous record. DRAM provides compelling exposure to specific AI memory companies like Micron, SK hynix, and Samsung, which is a primary driver of its appeal. As of May 11, 2026, DRAM has hit $6.5 billion in assets under management within 36 days of being on the market. Bloomberg’s Eric Balchunas noted that this is faster than any other ETF to reach the $6.5 billion milestone. This includes beating BlackRock’s (IBIT ), which did so in 43 days. How DRAM Stands Out in the Crowded AI FieldMany may be wondering how DRAM has been able to accomplish such a feat on short notice. Well, the fund provides a differentiated strategy for AI investing — focusing on companies engaged with AI, and computer memory and storage. To do so, the fund invests in companies engaged with memory chips relied upon for AI infrastructure and the ongoing buildout.  See more: New Memory ETF Dram Hits $1 Billion in Days Since Launch Furthermore, DRAM offers very specific exposure to a few notable companies. As of May 10, 2026, Micron, SK hynix, and Samsung held the lion’s share of weight within the fund’s portfolio, with Micron representing 27.33%, SK hynix covering 26.37%, and Samsung encompassing 20.42%.  This investment approach and portfolio allocation combo gives DRAM a couple of interesting use cases. Some may look to the fund as an alternative way to tap into AI momentum and innovation. Others could find the portfolio concentrations appealing, and use DRAM to ride out Micron momentum while still being engaged with other stocks.  See more: Kara Swisher Talks Tech Regulation & AI at Exchange Whatever the entry point for investors, DRAM’s momentum shows no signs of slowing down any time soon. The AI theme certainly won’t be waning with its growing demand, and DRAM’s approach to the sector, and compelling near-term results are attracting new investors on a regular basis. As of May 8, 2026, the fund’s NAV has risen 90.20% year to date.  For more news, information, and analysis, visit The Thematic Investing Content Hub.

More Commentary

Paltry S&P 500 Yield Makes This ETF Appealing
BY | ETF Database
05/11/2026 | 59 VIEWS
T. Rowe Price Crosses $25 Billion: A New Chapter for an Active Powerhouse
BY | ETF Database
05/11/2026 | 57 VIEWS
Rocket Labs (RKLB) Surge Boosts Space ETF UFO
BY | ETF Database
05/11/2026 | 34 VIEWS
View more Commentary

Search Commentary

Enter Keyword(s)
Filter Results

Performance data shown is past performance and is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore you have a gain or loss when you sell your shares. For standard quarterly performance, go to the fund's Snapshot page by clicking on the ETF/ETP's symbol.

ETFs may trade at a premium or discount to their NAV and are subject to the market fluctuations of their underlying investments.

For iShares ETFs, Fidelity receives compensation from the ETF sponsor and/or its affiliates in connection with an exclusive long-term marketing program that includes promotion of iShares ETFs and inclusion of iShares funds in certain FBS platforms and investment programs. Please note, this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral. Additional information about the sources, amounts, and terms of compensation can be found in the ETF's prospectus and related documents. Fidelity may add or waive commissions on ETFs without prior notice. BlackRock and iShares are registered trademarks of BlackRock, Inc. and its affiliates.

FBS receives compensation from the fund's advisor or its affiliates in connection with a marketing program that includes the promotion of this security and other ETFs to customers ("Marketing Program"). The Marketing Program creates incentives for FBS to encourage the purchase of certain ETFs. Additional information about the sources, amounts, and terms of compensation is in the ETF's prospectus and related documents. Please note that this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral.

News, commentary (including "Related Symbols") and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended to help self-directed investors evaluate exchange traded products (ETPs), including, but limited to exchange traded funds (ETFs) and exchange traded notes (ETNs). Criteria and inputs entered, including the choice to make ETP comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a particular security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating ETPs. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use. Determine which securities are right for you based on your investment objectives, risk tolerance, financial situation and other individual factors and re-evaluate them on a periodic basis.

Before investing in any exchange traded product, you should consider its investment objective, risks, charges and expenses. Contact Fidelity for a prospectus, offering circular or, if available, a summary prospectus containing this information. Read it carefully.